Back to News
Dec 11, 2025 4:00 PM

Natera New Test Data Could Change How Doctors Manage Breast Cancer

Natera Inc. (NASDAQ:NTRA) on Wednesday revealed initial translational research results from the international randomized Phase 3 PALLAS study.

Data were presented at the San Antonio Breast Cancer Symposium (SABCS).

These first data, generated from a U.S. biomarker cohort of 420 patients, show that molecular residual disease (MRD) status, measured by the Signatera Genome test after surgery (and adjuvant chemotherapy +/- radiation if administered), is a highly prognostic biomarker for distant recurrence risk in stage II–III, HR+/HER2- ...